Moleculin's Annamycin Shows Strong Efficacy in AML Trial — Moleculin Biotech, Inc.

Event summary

Moleculin's MIRACLE trial for Annamycin in relapsed/refractory AML showed complete remission rates three times higher than control.
Enrollment in Part A of the MIRACLE trial is on track to reach 90 patients by September 2026, with data readout expected between December 2026 and February 2027.
The company raised $9.3 million post-quarter-end, extending its cash runway into Q1 2027.
No cardiotoxicity observed in the MIRACLE trial despite high exposure levels.

The big picture

Moleculin's positive interim data for Annamycin in relapsed/refractory AML positions it as a potential disruptor in the treatment landscape. The absence of cardiotoxicity and strong remission rates address critical unmet needs, but the company must navigate regulatory hurdles and secure additional financing to sustain its pipeline advancements.

What we're watching

Regulatory Pathway: The pace at which Moleculin advances toward a Rolling New Drug Application for Annamycin will determine its timeline for potential accelerated approval.
Execution Risk: Whether Moleculin can sustain the strong investigator engagement and enrollment momentum in the MIRACLE trial through Part B initiation in 2027.
Financial Sustainability: How effectively Moleculin manages its cash position to fund operations beyond Q1 2027, given the need for significant additional financing.